INTRODUCTION: Hodgkin's lymphoma (HL) is one of the most curable malignancies 
with cure rates of above 85% across all stages. Bleomycin containing regimen is 
routinely employed in the treatment of HL. Pulmonary toxicity due to this drug 
is the most feared side effect in these regimens where the mortality rate is 
approximately 2%-3%. We have conducted this study to assess the genetic 
susceptibility among the Indian HL patients to bleomycin pulmonary toxicity 
(BPT).
MATERIALS AND METHODS: In a retrospective study conducted at a tertiary care 
hospital from South India between January 2013 and May 2019, we reviewed 100 HL 
patients who were treated with bleomycin-containing regimen (adriamycin, 
bleomycin, vinblastine, and dacarbazine or cyclophosphamide, vincristine, 
procarbazine, and prednisone/adriamycin, bleomycin, and vinblastine) for BPT.
RESULTS: A total of 100 patients with HL who had received bleomycin-containing 
regimen were analyzed, which included 23 females and 77 males. Twenty-nine 
patients had BPT and five deaths were attributed to the same. Radiology reports 
showed that 15 patients had acute BPT and eight patients had chronic changes. 
Four patients had rare findings of bleomycin-induced lung damage and computed 
tomography of the chest could not be done for two patients, whose chest X-ray 
showed features suggestive of BPT.
CONCLUSION: The incidence of bleomycin induced pulmonary toxicity and mortality 
was significantly higher in our study compared to that of other Western studies. 
This could be probably due to the increased susceptibility of the Indian 
patients to bleomycin induced lung damage. In a highly curable cancer such as 
HL, it is unacceptable to have such a high life-threating toxicity. Hence, an 
alternative chemotherapy regimen without bleomycin is to be explored which would 
prevent toxicity and hence the compromise on survival.